Request Demo

Last update 25 Jun 2025

Naloxone hydrochloride

Last update 25 Jun 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryNaloxone is a small molecule drug that acts as an antagonist at the μ opioid receptor, making it a potent tool in the treatment of opiate and drug overdose. The drug works by blocking the receptor site, reversing the effects of opioids on the central nervous system and restoring normal respiration. Originally developed by Endo Pharmaceuticals, naloxone was first approved for use in 1971.

Drug Type

Small molecule drug

Synonyms

Naloxone, Naloxone hydrochloride (JP17/USP), Naloxone hydrochloride dihydrate

+ [45]

Target

μ opioid receptor

Action

antagonists

Mechanism

μ opioid receptor antagonists(Mu opioid receptor antagonists)

Therapeutic Areas

Other DiseasesNeoplasmsImmune System Diseases+ [1]

Active Indication

Acute Lymphoblastic LeukemiaOpiate OverdoseOpioid abuse

Inactive Indication-

Originator Organization

Endo Pharmaceuticals, Inc.

Bexson Biomedical, Inc.

Active Organization

Hikma Pharmaceuticals LLC

Summit Biosciences, Inc.

Consegna Pharma, Inc.

+ [11]

Inactive Organization

Nasus Pharma Ltd.

Kaleo, Inc.

Emergent Devices, Inc.

+ [1]

License Organization

Summit Biosciences, Inc.ZMI Pharma, Inc.

Harm Reduction Therapeutics, Inc.

+ [10]

Drug Highest PhaseApproved

First Approval Date

United States (13 Apr 1971),

Opiate Overdose

RegulationPriority Review (United States), Fast Track (United States), Orphan Drug (European Union)

Structure/Sequence

Molecular FormulaC19H22ClNO4

InChIKeyRGPDIGOSVORSAK-STHHAXOLSA-N

CAS Registry357-08-4

207

Clinical Trials associated with Naloxone hydrochloride

NCT06251609

/ Not yet recruitingPhase 2IIT

Naloxone for Opioid Associated Out of Hospital Cardiac Arrest

The investigator's long-term goal is to conduct Naloxone for Opioid Associated out of Hospital Cardiac Arrest (NOPACA), a randomized, double blind, controlled trial to determine the efficacy of naloxone vs. placebo in Opioid Associated out of Hospital Cardiac Arrest. The investigative team plan to randomize patients in OHCA to early naloxone administration vs. placebo after initial resuscitation and measure ROSC and survival. Challenges to designing NOPACA include uncertainty regarding: 1) the available pool of participants and number of EMS agencies needed to meet enrollment targets; 2) acceptability among patients, EMS and Emergency Medicine provider stakeholders, and 3) estimates of the study outcomes needed for sample size estimates. Toward obtaining the necessary information to design NOPACA, the investigators propose a pilot RCT of participants at high risk for OA-OHCA to verify a reasonable recruitment rate; treatment fidelity and acceptability; and adequate retention and measurement of outcomes at follow up. The investigators propose incorporating hypothesis testing of the feasibility outcomes to determine progression to a definitive trial.

Start Date01 Nov 2026

Sponsor / Collaborator

The University of California, San Francisco

NCT04650841

/ Not yet recruitingEarly Phase 1IIT

The Role of the Opioid System in Placebo Effects on Pain and Social Rejection

The current study probes the involvement of the opioid system in placebo effects on social pain, using the opioid antagonist naloxone. 60 participants who recently experienced an unwanted breakup will experience rejection-related stimuli and receive painful heat and pressure stimuli during fMRI scanning. Participants will be randomized to receive either a naloxone or saline nasal spray, and be informed that the spray is either saline, or an effective pain and negative emotion reducing agent.

Start Date01 Sep 2025

Sponsor / Collaborator

Trustees of Dartmouth College

NCT07022717

/ Not yet recruitingNot ApplicableIIT

A Universal Primary Care Based Pilot Intervention to Reduce Youth Overdose Risk

Adolescent (ages 10-19) overdose deaths are the third leading cause of pediatric death and continue to rise in the United States. Healthcare providers have regular and trusted relationships with youth and have experience in providing public health injury prevention counseling. Youth have different motivations for using drugs, and many who experience fatal overdose do not have a history of opioid use. Primary care pediatric providers regularly provide developmentally appropriate injury prevention counseling for leading causes of pediatric fatal and nonfatal injury such as drowning prevention and firearms safety. However, there are no recommended, evidence-based overdose prevention interventions for youth, including in health care settings, even though research supports pediatricians and youth-serving clinicians providing harm reduction strategies such as naloxone distribution and overdose education. Among adults, overdose prevention education reduces overdose, is cost-effective, and can be learned by laypersons. Content commonly includes awareness of fentanyl in the drug supply, risk reduction (e.g., not using alone, risks of polysubstance use), and how to recognize and respond to an overdose, including the use of naloxone.
This study is a pilot two-arm cluster randomized controlled trial (RCT) of a brief overdose prevention education intervention that will be developed in collaboration with the Community Advisory Board (CAB). The primary outcome of this study is to assess the feasibility and acceptability of the brief youth overdose prevention intervention as measured by provider feasibility and acceptability as well as youth acceptability.

Start Date01 Jul 2025

Sponsor / Collaborator

Boston Medical Center

[+1]

100 Clinical Results associated with Naloxone hydrochloride

100 Translational Medicine associated with Naloxone hydrochloride

100 Patents (Medical) associated with Naloxone hydrochloride

30,758

Literatures (Medical) associated with Naloxone hydrochloride

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

Hailey-Hailey disease successfully treated with naloxone: 2 case reports and Review of the literature on efficacy of opioid receptor antagonist in Hailey-Hailey disease patients

Review

Author: Sheng, Nan ; Wu, Jianbing ; Fang, Fang ; Duan, Zhimin ; Xu, Beilei ; Li, Chengrang ; Song, Hao ; Zheng, Junyou

BACKGROUND:

Hailey-Hailey disease (HHD), a genetic blistering disease, is caused by a mutation in a calcium transporter protein in the Golgi apparatus encoded by the ATP2C1 gene. Clinically, HHD is characterized by flaccid vesicles, blisters, erosions, fissures, and maceration mainly in intertriginous regions. Some patients remain refractory to conventional treatments. Previously, a series of reports have confirmed naltrexone as an effective option for those patients. However, in China, naltrexone is unavailable in some hospitals and unaffordable for some patients.

OBJECTIVE:

To confirm naloxone as a treatment option for HHD, and assess the efficacy rate and safety of naltrexone for patients with HHD.

METHODS:

Two patients with biopsy-proven HHD received naloxone (2 mg/d, via intravenous infusion). We followed up with the two patients, assessing the change of skin lesions and obtaining photographs. We searched the PubMed databases using the keywords 'Hailey-Hailey disease' or 'benign familial pemphigus', and 'naltrexone' or 'naloxone', and reviewed English publications of reports and analyzed the efficacy and safety of naltrexone.

RESULTS:

Two patients prescribed naloxone showed completely remission in two weeks without any adverse reactions. The total remission rate of naltrexone for HHD is approximately 80%, without severe adverse effects.

CONCLUSION:

Naltrexone is effective and safe in the treatment of HHD. Naloxone, an analog of naltrexone, can also effectively and safely treat HHD, potentially offering a new therapeutic option for patients with refractory HHD.

31 Dec 2025·Future Science OA

Evaluating cytidine, uridine, and gabapentin combinations for pain modulation and p-CREB expression in neuropathic model

Article

Author: Alzaghari, Lujain F. ; Qnais, Esam Y. ; Barakat, Muna ; Al-Najjar, Mohammad A. A. ; Chellappan, Dinesh Kumar ; Alqudah, Abdelrahim ; Athamneh, Rabaa Y.

AIMS:

To evaluate the analgesic and neuroprotective effects of cytidine, uridine, and gabapentin-administered alone and in combination-in models of diabetic neuropathy and formalin-induced acute and inflammatory pain.

MATERIALS & METHODS:

Oral doses of cytidine, uridine, and gabapentin (100 mg/kg each) were administered to rats with streptozotocin-induced diabetic neuropathy and in a formalin test model. Behavioral responses were recorded at 30, 60, and 120 minutes following treatment after five weeks of diabetes induction. Spinal cord p-CREB expression was measured to assess molecular changes, and pretreatments with naloxone, yohimbine, and methysergide were employed to explore opioid, adrenergic, and serotonergic contributions.

RESULTS:

All treatments significantly reduced formalin-induced pain in both acute and inflammatory phases (p < 0.05; p < 0.001) and increased mechanical pain thresholds in the diabetic neuropathy model at all-time points (p < 0.05). Combination therapy proved more effective than gabapentin alone (p < 0.05) and was associated with decreased spinal p-CREB levels, indicating altered anti-nociceptive signaling.

CONCLUSIONS:

The combined use of cytidine, uridine, and gabapentin enhances analgesia and neuroprotection compared to monotherapy, supporting its potential as a novel, analgesic-free treatment strategy for diabetic neuropathy.

01 Nov 2025·NEUROPHARMACOLOGY

Reversal of a synthetic opioid overdose: Insights from a validated translational model

Article

Author: Purohit, Prasad ; de la Peña, Amparo ; Skolnick, Phil ; Laffont, Celine M

Synthetic opioids are linked to >90 % of opioid overdose deaths in the United States. A FDA's validated translational model of synthetic opioid overdose, expanded to include intranasal reversal agents, was used to compare the effectiveness of FDA-approved intranasal naloxone (4 mg) and intranasal nalmefene (3 mg nalmefene hydrochloride, 2.7 mg base). In the absence of intervention, simulations using various intravenous doses of fentanyl and carfentanil predicted an incidence of cardiac arrest ranging from 18 % to 90 % in chronic opioid users and from 40 % to 96 % in opioid naïve subjects. Across dosing scenarios, intranasal nalmefene produced large and clinically meaningful reductions in the incidence of cardiac arrest compared to intranasal naloxone; the greatest differences in effectiveness were manifested at the higher doses of synthetic opioids. In the original publication describing FDA's model, the reversal agent was administered 1 min after ventilation was reduced to 40 % of baseline. Introducing further delays in intervention reduced the effectiveness of both reversal agents. Simulations showed intranasal nalmefene reduced the incidence of cardiac arrest compared to intranasal naloxone when intervention was delayed 2.5-3 min; delays ≥7.5 min abolished the effectiveness of both agents. The model was also used to predict the duration of brain hypoxia following a synthetic opioid overdose in a typical chronic opioid user. Across those simulations, intranasal nalmefene was generally more effective than intranasal naloxone in reducing brain hypoxia duration. These findings illustrate both the relative effectiveness of nalmefene and naloxone in reversing a synthetic opioid overdose and the importance of rapid intervention.

500

News (Medical) associated with Naloxone hydrochloride

23 Jun 2025

·www.prnewswire.com

Navamedic ASA expands into addiction treatment through the acquisition of the business of dne pharma and announces a partially underwritten rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. OSLO, Norway, June 23, 2025 /PRNewswire/ -- Navamedic ASA (OSE: NAVA) ("Navamedic" or the "Company"), a Nordic pharmaceutical company and trusted supplier of high-quality products to hospitals and pharmacies, has today entered into an agreement to acquire the business of dne pharma as ("dne pharma") for a total consideration of up to NOK 225 million (the "Acquisition"). The purchase price is payable in instalments, whereby NOK 185 million is payable at closing of the Acquisition, and the remaining NOK 40 million is payable in two tranches subject to achievement of certain agreed sales volumes for the acquired products. dne pharma is a Norwegian company focused on addiction treatment pharmaceuticals. The Acquisition The Acquisition encompasses dne pharma's business, including product portfolio, key employees and all essential contracts of the business, intellectual property, licenses, and distribution agreements. The product portfolio includes prominent products such as Ventizolve® (intranasal naloxone spray for opioid overdose reversal), Levopidon® (levomethadone), and Metadon Dne (methadone) for opioid substitution therapy. The Acquisition (i) marks Navamedic's entry into the fast-growing field of addiction treatment and (ii) supports Navamedic's ambition to become a leading Nordic provider of specialized, high-quality products to hospitals and pharmacies. In 2024, the business being acquired generated net sales of NOK 62 million and is expected to be an important contributor in reaching Navamedic's NOK 1 billion revenue target. Aligned with Navamedic's strategy of expanding its portfolio of proprietary products, the Acquisition is also expected to be accretive to Navamedic's gross margins. Upon integrating the product portfolio into Navamedic's platform, significant synergies are expected to be realised and Navamedic anticipates an EBITDA contribution on an annual basis of approx. NOK 25 million based on the 2024 net sales, with the expectation to increase the EBITDA contribution at least with revenue growth. "This acquisition gives us a strong strategic position in an important therapeutic area," said Kathrine Gamborg Andreassen, CEO of Navamedic. "Addiction treatment is a growing therapeutic area with significant impact on people's lives, and dne pharma's products align well with our mission to deliver high-quality products where they are most needed." The acquired business will be integrated into Navamedic's existing commercial platform, enabling rapid market access and geographic expansion across the Nordics and selected European markets. The products of the acquired business fit well into the existing Navamedic product portfolio and set-up, both with regard to geographical footprint, logistics/warehousing and tender management. There are significant synergies within these areas that are expected to add value. Furthermore, this acquisition adds to the range of products Navamedic now wholly owns, which is part of the long-term strategy for the Company. The Acquisition will be financed through a combination of new debt in the amount of NOK 110 million from Nordea Bank Abp, filial i Norge ("Nordea") and a rights issue as further described below (the "Rights Issue"). Navamedic will also be granted a bridge loan from Nordea enabling completion of the Acquisition before completion of the Rights Issue. Navamedic has retained DNB Carnegie, a part of DNB Bank ASA ("DNB Carnegie") and Nordea Corporate Finance, a part of Nordea Bank Abp, filial i Norge as managers for the Rights Issue (the "Managers") and DNB Carnegie as financial advisor in connection with the Acquisition. Advokatfirmaet Thommessen AS is engaged as Norwegian legal counsel for the Company in connection with the Acquisition and the Rights Issue. Completion of the Acquisition is conditional upon approval of the Rights Issue by an extraordinary general meeting of the Company to be held on 14 July 2025 (the "EGM") and is expected to occur on 15 July 2025. Navamedic has agreed to pay dne pharma a compensation of NOK 5 million in the event that Navamedic terminates the asset purchase agreement for the Acquisition due to lack of approval of the Rights Issue by the EGM. The Rights Issue General The board of directors of Navamedic (the "Board") has, in order to part-finance the Acquisition, resolved to propose that new equity is raised through the partially underwritten Rights Issue of new shares with preferential rights for existing shareholders to raise gross proceeds of between approximately NOK 110 million and NOK 130 million. The minimum amount of NOK 110 million has been underwritten by the Company's largest shareholder, Kistefos AS, as further described below. The Rights Issue is subject to shareholder approval at the EGM and publication of the Prospectus (as defined below). Notice of the EGM, including proposed resolutions and further information regarding the Rights Issue, is expected to be sent to the shareholders today. Certain existing shareholders, including Kistefos AS and the members of the Board and the Company's management, currently representing in total 27.32% of the shares in the Company, have undertaken to vote in favour of the Rights Issue at the EGM. Proceeds The maximum gross proceeds from the Rights Issue will be approximately NOK 130 million and the minimum gross proceeds will be approximately NOK 110 million. The net proceeds from the Rights Issue will be used to repay the bridge loan from Nordea, which will be used as partial payment of the portion of the purchase price payable at the closing of the Acquisition. Any proceeds raised in excess of NOK 110 million will be used for general corporate purposes. Terms and conditions The subscription price in the Rights Issue will be NOK 21.50 per share, which has been determined based on the current market price. Each shareholder of the Company who is not resident in a jurisdiction where such offering would be unlawful or, in jurisdictions other than Norway, require any prospectus, filing, registration or similar action, will be granted tradeable subscription rights ("Subscription Rights") in proportion to the number of existing shares held at the date of the EGM, as registered in the Norwegian Central Securities Depository (ES-OSL) at the end of the second trading day on Euronext Oslo Børs thereafter (the "Record Date"), cf. section 10-4 of the Norwegian Public Limited Liability Companies Act. The Company's shares are expected to trade exclusive of the right to receive Subscription Rights from and including 15 July 2025. Each Subscription Right will, subject to applicable securities laws, give the right to subscribe for and be allocated one new share in the Rights Issue. Oversubscription and subscription without subscription rights will be permitted, but with no guaranteed allocation and with allocation to Kistefos AS and any additional underwriters for the underwritten amount prior to allocation to subscriptions without subscription rights. The subscription rights will be applied for trading and listing on Euronext Oslo Børs from and including the first day of the subscription period and until 16:30 (Oslo time) four trading days prior to the expiry of the subscription period. The Company will prepare and publish an EEA prospectus for the offering and listing of the shares issued in the Rights Issue that will include the full terms and conditions of the Rights Issue (the "Prospectus"). The Prospectus will be subject to approval by the Norwegian Financial Supervisory Authority (the "NFSA") before publication. All dates and other figures concerning the Rights Issue included herein remain tentative and subject to change. Any changes will be announced at the EGM or through stock exchange announcements. Underwriting The Company's largest shareholder, Kistefos AS, has, subject to customary conditions, underwritten the minimum amount of NOK 110 million in the Rights Issue. New shares subscribed for and allocated to Kistefos AS in the Rights Issue will reduce the underwriting commitment. An underwriting fee of 5 per cent of the underwritten amount (with a reduced fee payable if the EGM does not approve the Rights Issue within a period of four weeks) will be paid for the underwriting commitment, payable in new shares to be issued at the same subscription price as in the Rights Issue. These new shares will be in addition to the shares to be issued in the Rights Issue. The underwriting may during the coming week be supplemented with additional existing large shareholders as underwriters on the same terms as Kistefos AS, and Kistefos AS has agreed that its underwriting commitment in such event and if required may be scaled down. Timeline According to the current tentative timetable, and subject to the approval by the EGM, the Company's shares are expected to trade exclusive of Subscription Rights from and including 15 July, the record date for the Subscription Rights is expected to be 16 July 2025 and the subscription period for the Rights Issue is expected to commence on or around 22 September 2025 and end on or around 6 October 2025. The period during which the Subscription Rights are to be tradable is expected to commence on or around 22 September 2025 and end on or around 30 September 2025. The Subscription Period may not be shortened, but the Company's board of directors may extend the Subscription Period if required. Any changes will be announced through stock exchange announcements. Presentation Navamedic will host two online presentations to present the acquisition on Tuesday 24 June 2025 at 12:00 CEST (in Norwegian) and 13:00 CEST (in English). The presentation will be held by CEO, Kathrine Gamborg Andreassen and CFO, Lars Hjarrand. To attend the webcast, please send an e-mail to [email protected]. For further information, please contact: Kathrine Gamborg Andreassen, CEO, Mobile: +47 951 78 880 E-mail: [email protected] Lars Hjarrand, CFO, Mobile: +47 917 62 842 E-mail: [email protected] This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Lars Hjarrand, CFO of the Company, on 23 June 2025 at 08:00 hours CEST on behalf of the Company. About Navamedic Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit . About dne pharma dne pharma is a Norwegian developer and distributor of addiction and pain therapies, including opioid substitution treatments and emergency overdose medications. Its portfolio supports public health efforts across Scandinavia and beyond. For more information, please visit . dne pharma's wholly owned subsidiary, Pharma Production AS, will continue to manufacture and supply the product portfolio being acquired by Navamedic, as well as concentrate on contract manufacturing and development services, including analytical services, supporting the long-term need for national pharmaceutical production capacity. . - IMPORTANT INFORMATION - This announcement does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities of the Company in the United States or any other jurisdiction. Copies of this document may not be sent to jurisdictions, or distributed in or sent from jurisdictions, in which this is barred or prohibited by law. The securities of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"). The securities of the Company have not been, and will not be, registered under the U.S. Securities Act. Any sale in the United States of the securities mentioned in this communication will be made solely to "qualified institutional buyers" as defined in Rule 144A under the U.S. Securities Act. No public offering of the securities will be made in the United States. Any offering of the securities referred to in this announcement will be made by means of the Prospectus. This announcement is an advertisement and is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on prospectuses to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (as amended) as implemented in any EEA Member State (the "Prospectus Regulation"). Investors should not subscribe for any securities referred to in this announcement except on the basis of information contained in the Prospectus. Copies of the Prospectus will, following publication, be available from the Company's registered office and, subject to certain exceptions, on the website of the Managers. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. In the United Kingdom, this communication is only addressed to and is only directed at Qualified Investors who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as "Relevant Persons"). These materials are directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this announcement relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this communication must satisfy themselves that it is lawful to do so. This document is not for publication or distribution in, directly or indirectly, Australia, Canada, Japan, the United States or any other jurisdiction in which such release, publication or distribution would be unlawful, and it does not constitute an offer or invitation to subscribe for or purchase any securities in such countries or in any other jurisdiction. In particular, the document and the information contained herein should not be distributed or otherwise transmitted into the United States or to publications with a general circulation in the United States of America. The Managers are acting for the Company in connection with the Rights Issue and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients or for providing advice in relation to the Rights Issue or any transaction or arrangement referred to in this announcement. Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "anticipate", "believe", "continue", "estimate", "expect", "intends", "may", "should", "will" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date and are subject to change without notice. This announcement is made by and is the responsibility of, the Company. Neither the Managers nor any of their affiliates makes any representation as to the accuracy or completeness of this announcement and none of them accepts any responsibility for the contents of this announcement or any matters referred to herein. This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy, fairness or completeness. Neither the Managers nor any of their respective affiliates accepts any liability arising from the use of this announcement. This information was brought to you by Cision Navamedic ASA expands into addiction treatment through the acquisition of the business of dne pharma and announces a partially underwritten rights issue NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, News Powered by Cision WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Acquisition

11 Jun 2025

·www.prnewswire.com

Elysium Therapeutics' Investor Webcast Highlights "Fentanyl Rebound" as Key Challenge in Reducing Opioid Overdose Hospitalizations and Deaths

Elysium's Synthetic Opioid Overdose Prevention and Reversal (SOOPR™) technology designed specifically to combat oral fentanyl overdose LYONS, Colo., June 11, 2025 /PRNewswire/ -- Elysium Therapeutics, an emerging biopharmaceutical company developing treatments specifically designed to rescue and reverse overdoses caused by oral opioids, including synthetic opioids like fentanyl, recently hosted a webcast to educate investors and pharmaceutical leaders on the pressing need to develop overdose rescue therapies designed specifically for synthetic opioids, like fentanyl. Entitled, "Innovating Solutions to Combat Fentanyl Rebound" and led by Greg Sturmer, CEO, the presentation noted that short-acting opioid antagonists like Narcan® and Opvee® are frequently ineffective in the management of synthetic opioid overdoses1, with 20 to 45% of overdose victims initially rescued with naloxone experiencing a re-narcotization event. Sturmer commented: "When fentanyl is taken orally, individuals can face a danger zone, a period of respiratory depression that can last six to eight hours, which far outlasts the window provided by currently available rescue agents that only last, at most, 30 minutes. The result is nearly half of those initially given a dose of today's rescue medications experience a rebound or re-narcotization event, which can lead to a hypoxic brain injury, cardiovascular toxicity or death." To address this critical shortcoming, Elysium designed its Synthetic Opioid Overdose Prevention and Reversal (SOOPR™) technology to be both faster acting and with the potential to offer overdose protection out to approximately 24-hours. Additionally, Elysium designed SOOPR with an intramuscular route of administration, which grants more reliable dosing, in comparison to intranasal administration, which can lead to partial and uncertain dosing in high stress settings. Sturmer added: "SOOPR was designed specifically for synthetic opioids, which are now the number one killer of adults aged 18 to 45 in the U.S. The need for a rapid-acting, long-duration reversal agent, such as SOOPR, is extreme given its potential to reduce the likelihood of hypoxic brain injury, cardiovascular events, re-narcotization, and death. Recognizing this opportunity, Elysium is planning to rapidly advance the SOOPR clinical program along a timeline that could enable the technology to reach the market in the next two to three years." About SOOPR™ (Synthetic Opioid Overdose Prevention and Rescue) SOOPR (Synthetic Opioid Overdose Prevention and Reversal) is a rapid-onset, long-acting rescue agent specifically designed to address overdose from synthetic opioids, including oral fentanyl. SOOPR utilizes a proprietary long-acting naloxone reversal formulation with faster onset kinetics versus Narcan® delivered via long-acting injection (LAI) technology. The technology is designed to rapidly restore respiration and provide 18 – 24 hours of effective opioid blockade to minimize the risk of re-narcotization, while also providing protection from same-day re-use of opioids. SOOPR has been endorsed by first responders and OUD treatment professionals as the effective solution urgently needed to address the global opioid overdose epidemic. About Elysium Therapeutics Elysium is an emerging biopharmaceutical company developing treatments specifically designed to rescue and reverse overdoses caused by oral synthetic opioids, including fentanyl. Elysium is working to establish new standards of safety in the opioid industry by developing SMART™ (Safer Medicines Alleviate Risks and Trauma) products, first- and best-in-class medicines that address the limitations and dangers associated with opioids and overdose rescue agents to reduce suffering from opioid-use disorder, opioid overdose, and acute pain. Elysium's lead technology, SOOPR™ (Synthetic Opioid Overdose Prevention and Reversal), is a long-acting opioid antagonist specifically designed to address oral synthetic opioid, including fentanyl, overdose. Tens of thousands of unnecessary overdose deaths each year exemplifies the critical shortcomings of currently available rescue agents, including naloxone and nalmefene. In addition, Elysium is developing oral-overdose protected (O2P™) hydrocodone for the treatment of moderate-to-severe acute pain. For more information, please visit . ¹ Rachael Rzasa Lynn and JL Galinkin Ther Adv Drug Saf 2018, Vol. 9(1) 63–88. SOURCE Elysium Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

06 Jun 2025

·www.prnewswire.com

Victoria's Voice Foundation Marks National Naloxone Awareness Day on June 6 with Special Event on Capitol Hill

Annual Awareness Day Focusing Attention on the Drug Crisis and Importance of Lifesaving Opioid Overdose Reversal Medications was Launched by Victoria's Voice with Support from a Bipartisan Congressional Resolution Over 140 Iconic Buildings and Landmarks Nationwide to Shine Purple in Recognition of Awareness Day WASHINGTON, June 6, 2025 /PRNewswire/ -- Victoria's Voice Foundation marked National Naloxone Awareness Day on June 6 with a special event on Capitol Hill, bringing together families affected by the opioid crisis, advocates, lawmakers, law enforcement and other first responders. The awareness day is a vital time to heighten awareness of the risks of opioid overdoses and the urgency of expanding access to and the use of lifesaving overdose reversal medicines. It was launched in 2023 by Victoria's Voice Foundation with support from a bipartisan congressional resolution recognizing the awareness day annually. Naloxone, commonly sold over the counter under the brand name NARCAN® Nasal Spray, is a critical tool in preventing fatal opioid overdoses – and is credited with helping drive the recent 27% decline in U.S. drug overdose deaths. Naloxone nasal spray helps restore normal breathing in a person experiencing an opioid overdose. It is safe, easy to administer and non-addictive – and designed for use by bystanders and first responders alike. This is crucial because nearly 40% of fatal overdoses occur in the presence of someone else, according to the CDC. "We must continue to expand naloxone awareness, access and use so we can save as many lives as possible from opioid overdose," said Jackie Siegel, who co-founded Victoria's Voice with her late husband, David, after losing their daughter, Victoria, 18, to an accidental drug overdose on June 6, 2015. On the day she died, Victoria had a pulse when first responders arrived and found her unresponsive, but they were not equipped with naloxone, and Victoria became another statistic. Jackie added: "I am deeply grateful to the members of the U.S. Senate who introduced a bipartisan resolution declaring June 6 as National Naloxone Awareness Day – and to all those on the front lines of the crisis. While today is especially bittersweet as we mark 10 years since Victoria's passing, I find comfort and strength in knowing that her legacy is that because of her death, many more people will live." Victoria's Voice is dedicated to drug awareness and prevention and saving lives from overdose. Since its founding, Victoria's Voice has positively impacted over 1.5 million children and parents through its education programs. Additionally, David Siegel was at the forefront of the efforts to increase naloxone access and use – especially among law enforcement in Florida and nationwide – and inform about its lifesaving power. The 2025 federal resolution was introduced by U.S. Senators Rick Scott (R-FL), Ed Markey (D-MA), Jim Justice (R-WV), Maria Cantwell (D-WA), Ashley Moody (R-FL), Sheldon Whitehouse (D-RI), James Lankford (R-OK), Ron Wyden (D-OR), Angus King (I-ME) and Raphael Warnock (D-GA). Speakers at yesterday's resolution ceremony in the Hart Senate Office Building included Jackie Siegel, Sen. Rick Scott (R-FL), and Seminole County (FL) Sheriff Dennis Lemma, a statewide and national leader on responding to and preventing overdoses, and a Victoria's Voice board member. Other speakers included Sen. Ashley Moody (R-Fl), Rep. Sharice Davids (D-KS), Virginia First Lady Suzanne S. Youngkin, and Sir Edwards, Mayor-President of Baton Rouge (LA). "It is a privilege to join Victoria's Voice Foundation in recognizing National Naloxone Day and honor the life of Victoria, a young life lost to the devastating opioid epidemic. It is every parent's worst nightmare to lose their child, and it is remarkable to see how the Siegel family has turned their grief into a mission to educate others about the dangers of the opioid crisis so other families don't experience this same heartbreak," said Sen. Rick Scott (R-FL). Scott added: "This year was also the first Naloxone Awareness Day since the passing of my friend and Victoria's Voice founder, David Seigel. Ann and I were honored to donate a portion of my Senate salary to Victoria's Voice to support its cause and pay tribute to David's incredible work and legacy. I am proud to work with the foundation to raise awareness on the crisis and life-saving tool of Naloxone, which is critical in our fight to stop loss of life from opioids." "In every state, there are families, friends, and neighbors who are grieving the loss of a loved one to overdose. Naloxone can save lives but only if we get this lifesaving medication in people's hands. We need people to have access to naloxone, be able to afford it, and know how to use it," said Senator Ed Markey (D-MA). "I'm proud to join my colleagues in recognizing June 6 as Naloxone Awareness Day. This is an essential step in spreading awareness and giving communities the tools they need to save lives in the face of the opioid epidemic." National Naloxone Awareness Day is proudly sponsored by Emergent BioSolutions, the makers of NARCAN® Nasal Spray. "On National Naloxone Awareness Day, we have the opportunity to reinforce opioid emergency preparedness and make sure stakeholders across all sectors – from government officials to business leaders and local organizations – feel equipped with the tools they need to be ready to rescue not only today, but every day," stated Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. "We're proud of the work Victoria's Voice Foundation is doing year-round and we're honored to use this key moment in time to raise awareness and keep our communities safe together." In support of National Naloxone Awareness Day, over 140 iconic buildings, landmarks, bridges, monuments, parks, museums, city halls, downtown hubs and skylines nationwide will glow purple. From Niagara Falls, Baltimore's City Hall Dome, and the Kia Center in Victoria's Voice's Orlando hometown, to the Louisiana State Capitol, Chicago's 875 North Michigan Avenue and the Hawaii Convention Center, lights will be illuminated purple in a powerful display of awareness, unity and hope. Additionally, proclamations were issued by counties, cities and states including Orange County (FL), Baltimore, Kansas City, and the State of Illinois. For more information about National Naloxone Awareness Day, visit . About Victoria's Voice Foundation David and Jackie Siegel established Victoria's Voice Foundation after losing their 18-year-old daughter to an accidental drug overdose on June 6, 2015. Victoria's Voice is dedicated to providing support and resources to families affected by substance use. Since its founding, Victoria's Voice has positively impacted over 1.5 million parents and children through its education programs. For more information, visit or @victoriasvoicefoundation. #VictoriasVoiceFoundation #GetGiveSave. About NARCAN® Nasal Spray NARCAN® Naloxone HC1 Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN® Nasal Spray is not a substitute for emergency medical care. Repeat dosing may be necessary. Use as directed. SOURCE Victoria’s Voice Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug Approval

100 Deals associated with Naloxone hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01340	Naloxone hydrochloride	A06AH04 V03AB15	DB01183

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute Lymphoblastic Leukemia	Canada	Hikma Pharmaceuticals LLC	01 Feb 2025
Opiate Overdose	United States	Emergent Devices, Inc.	13 Apr 1971

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Opioid abuse	Preclinical	United States	Consegna Pharma, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03751111 (CTgov)	Phase 1/2	Pruritus \| Pruritus Ani	126	Naloxone (Naloxone)	pqcekkuqtb(naygeilris) = wczwwkpyjd usfyaucenw (ixmzumbpbw, 2.15) View more	-	20 Apr 2025
				Placebo (Placebo)	pqcekkuqtb(naygeilris) = ilkvezswpx usfyaucenw (ixmzumbpbw, 1.99) View more
NCT04473950 (CTgov)	Phase 1	Opioid-Related Disorders \| Chronic Pain	10	Placebo+Naloxone Hydrochloride (Pain Group)	bmwwartyqi(rqibdnaebc) = oneymfvopw awrwzypmwg (hxxxpqxvqb, 1.17) View more	-	26 Mar 2025
				Placebo+Naloxone Hydrochloride (No Pain Group)	bmwwartyqi(rqibdnaebc) = fwzivygucn awrwzypmwg (hxxxpqxvqb, 0.92) View more
NCT03176316 (FusionIleus, CTgov)	Phase 4	Ileus	53	Naloxone	aowxbbtcua = jnekmjgame tyqmhimymp (gkstxojceg, txqyzvnfta - ufsbaxurmp) View more	-	01 Jul 2024
NCT03149770 (CTgov)	Phase 2	Diabetes Mellitus, Type 1 \| Hypoglycemia	30	Naloxone (Naloxone)	aqfijqvnbx(occuvtwjki) = jzioecziij oewwiotuwg (mlslufnixl, 12) View more	-	16 Apr 2024
				placebo (Placebo)	aqfijqvnbx(occuvtwjki) = eahsbelbmx oewwiotuwg (mlslufnixl, 13) View more
NCT04764630 (Pubmed \| JAMA Netw Open)	Phase 1	Opiate Overdose	21	1 dose at 0, 2.5, 5, and 7.5 minutes	zopkhlfjnm(yhyetrbxvq) = cbdhdybxon nunjymjrmf (layyzniwjk )	-	23 Jan 2024
				2 doses at 0 and 2.5 minutes	zopkhlfjnm(yhyetrbxvq) = wicqdnvxmm nunjymjrmf (layyzniwjk )
NCT03570099 (Pubmed \| BMJ Open)	Not Applicable	Opiate Overdose	-	Take-home naloxone distribution	yfryzlhpyk(hnpegxgfbh) = phhgphtndk ojmzujgxxj (gqikfqluta )	-	01 Jan 2024
				intranasal naloxone (Control period (2013-2017))	yfryzlhpyk(hnpegxgfbh) = abywwfbfeb ojmzujgxxj (gqikfqluta )
ADA2023	Not Applicable	Pure Autonomic Failure	-	Intranasal naloxone (IN)	djltvjbidm(xjnlwacmew) = eifxrrnewc itwleixxdh (rtzwouqvkq ) View more	-	20 Jun 2023
				Placebo	djltvjbidm(xjnlwacmew) = panggctxmn itwleixxdh (rtzwouqvkq ) View more
NCT04713709 (Corporate Publications) Manual	Phase 1	Opiate Overdose	56	FMXIN001	jswnjvewpp(gjxndsypit) = yvyjywoltx aqphmhcvuj (urzkfawiki ) View more	Similar	28 Jul 2022
				NARCAN	jswnjvewpp(gjxndsypit) = xsdhubsssu aqphmhcvuj (urzkfawiki ) View more
NCT04764630 (CTgov)	Phase 1	-	21	naloxone (A. Four Naloxone Nasal Spray Doses (1 Every 2.5 Min))	dfpjxejvof(snqteattze) = cvxfaotjzo wkerhvrtch (jlczhoynrl, 70) View more	-	15 Jul 2022
				naloxone (C. Two Naloxone Nasal Spray Doses (1 Every 2.5 Min))	dfpjxejvof(snqteattze) = ynphkvodsx wkerhvrtch (jlczhoynrl, 159) View more
NCT02805972 (BEE, CTgov)	Phase 2	Obesity	41	Placebo+Naloxone (Placebo, Then Naloxone)	hcxildmxrc(qtafwfpmby) = mgxrcnyhtl qlcrzkafhd (vrlninhlof, jietcfqxhk - juudcvppmy) View more	-	03 Nov 2021
				Placebo+Naloxone (Naloxone, Then Placebo)	hcxildmxrc(qtafwfpmby) = uqhanruwxo qlcrzkafhd (vrlninhlof, qmbuljfllc - yloaiouefu) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis